|Exchange:||NASDAQ national market|
|Vical Incorporated, a Delaware corporation, was incorporated in April 1987 and has devoted all of its resources since that time to its research and development programs. The Company researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Company currently has five active independent clinical and preclinical development programs in the areas of infectious disease and cancer including: A fully enrolled Phase 3 clinical trial using its Allovectin-7(r) immunotherapeutic in patients with metastatic melanoma which has been funded, up to certain limits, by AnGes MG, Inc., or AnGes, through cash payments and equity investments under a research and development agreement; A fully enrolled Phase 2 clinical trial using TransVax(tm), its cytomegalovirus, or CMV, therapeutic DNA vaccine, in patients undergoing hematopoietic cell transplants; Completed Phase 1 clinical trials using H5N1 pandemic influenza DNA vaccine formulated with its proprietary Vaxfectin(r) adjuvant; A preclinical program using H1N1 pandemic influenza DNA vaccine formulated with proprietary Vaxfectin(r) adjuvant; and A preclinical program using CyMVectin(tm) prophylactic vaccine formulated with the proprietary Vaxfectin(r) adjuvant to prevent CMV infection before and during pregnancy to preclude fetal transmission. The Company is subject to various federal, state and local laws, regulations, and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its research.|
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.